Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped

This article was originally published in The Pink Sheet Daily

Executive Summary

Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.
Advertisement

Related Content

Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel
PanGenetics "Experiment" Winding Down, CEO Kevin Johnson to Pursue Asset-Centric Model at Index Ventures
No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?
Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting
Best Laid Plans: Pfizer's Torcetrapib Tanks
Best Laid Plans: Pfizer's Torcetrapib Tanks

Topics

Advertisement
UsernamePublicRestriction

Register

PS070806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel